METTL2A is required for the proliferation of pancreatic cancer cells. (A) Heat map displaying the relative expression levels of m³C writers across various cancer types in comparison with their normal tissues. Cancer types are arranged based on their relative expression in cancer versus normal tissue. (B) The association between m³C writer expression and patient prognosis across various cancer types. Cancer types associated with a favorable prognosis in the high-expression group (hazard ratio < 0 and P-value < 0.05 in the Cox proportional hazards model) are highlighted in red, whereas those associated with a poor prognosis in the high-expression group (hazard ratio > 0 and P-value < 0.05) are highlighted in blue. (C) Violin plots depicting the expression levels of m³C writers in pancreatic cancerous and normal tissues. (T) Tumor tissues, (N) normal tissues. (D) Kaplan–Meier plots showing the correlation between m³C writer expression and patient survival in pancreatic cancer. The red line represents patients with high m³C writer expression, and the blue line represents those with low expression; n (high) = 91, n (low) = 92. (E) The viability of AsPC-1, PANC-1, and SUIT-2 cells transfected with siRNAs targeting METTL2A, assessed by CellTiter-Glo assays. Results are expressed as the mean ± standard deviation (s.d.). (n = 4), (****) P < 0.0001.